Recent Updates
Recently added Catalysts

ALXN1920

Phase 2

Primary Membranous Nephropathy | Small molecule | Nephrology |AstraZeneca PLC|Last Updated: Jun 18, 2026

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedDouble-BlindCONTROLLEDDMC
Total Trials1
Total Enrollment30

FDA Designations

No designations recorded

Clinical trial landscape

ALXN1920 · 2 trials · 2 indications

Phase 2 1Phase 1 1
NCT07157787Study of ALXN1920 in Adult Participants With Primary Membranous Nephropathy (PMN)Primary Membranous Nephropathy
RECRUITING30 Analytics
PHASE2RECRUITING
Study of ALXN1920 in Adult Participants With Primary Membranous Nephropathy (PMN)
Primary Membranous Nephropathy
NCT0715778730
Unlock trial analytics

Study Endpoints

Primary Endpoints

Change From Baseline in Proteinuria Based on 24-hour UPCR at Week 26
Baseline, Week 26
Number of participants with Adverse events (AEs)
Up to End of study visit (Day 29)

To assess the safety and tolerability of single ascending doses of ALXN1920.

Secondary Endpoints

Change From Baseline in Proteinuria Based on 24-hour UPCR at week 12
Baseline and week 12
Change From Baseline in Proteinuria Based on Spot UPCR at Week 12 and week 26
Baseline, Week 12 and Week 26
Change From Baseline in Serum Albumin at Week 12 and week 26
Baseline, week 12 and Week 26
Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingQUADRUPLE
ModelPARALLEL
PurposeTREATMENT

Treatment Arms

ArmTypeDescription
ALXN1920EXPERIMENTALParticipants will receive ALXN1920 subcutaneous (SC) and background treatment of ACE/ARB and Rituximab.
PlaceboEXPERIMENTALParticipants will receive placebo subcutaneous (SC) and background treatment of ACE/ARB and Rituximab.
Cohort 1EXPERIMENTALParticipants will receive a single dose of ALXN1920.
Cohort 2EXPERIMENTALParticipants will receive a single dose of ALXN1920.
Cohort 3EXPERIMENTALParticipants will receive a single dose of ALXN1920.
Cohort 4EXPERIMENTALParticipants will receive a single dose of ALXN1920.
Cohort 5EXPERIMENTALParticipants will receive a single dose of ALXN1920.
Cohort 6: Japanese CohortEXPERIMENTALJapanese participants will receive a single dose of ALXN1920.
Pooled PlaceboPLACEBO_COMPARATORParticipants will receive Placebo.

Interventions

NameTypeDescription
ALXN1920DRUGParticipants will receive ALXN1920 SC infusion.
PlaceboDRUGParticipants will receive Placebo SC infusion.
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to 75 Years
SexALL
Healthy VolunteersNo
Study Sites40

Inclusion Criteria: * Participants who have a documented diagnosis of PMN, established by positive antiPLA2R antibody level (\> 20 RU/mL) at Screening, which must be confirmed by a central laboratory * Participants are willing to receive the background Standard of Care (SoC) * Participants at high ...

Countries:United StatesArgentinaAustraliaBrazilChinaFranceItalySpainTaiwanUnited KingdomNew Zealand
Unlock Eligibility Criteria

Recent Changes (Last 90 Days)

LOWJun 18, 2026NCT07157787lastUpdatePostDate: changed
LOWJun 18, 2026NCT07157787lastUpdatePostDate: changed
LOWJun 18, 2026NCT07157787lastUpdatePostDate: changed

Frequently asked questions about ALXN1920

What is ALXN1920 used for?

ALXN1920 is an investigational monoclonal antibody being studied for the treatment of primary membranous nephropathy (PMN), a kidney disease. It is also being evaluated in healthy participants to assess its safety, tolerability, pharmacokinetics, and pharmacodynamics. The drug is currently in clinical development and is not yet approved by regulatory authorities.

Who is developing ALXN1920?

ALXN1920 is being developed by AstraZeneca PLC, a biopharmaceutical company traded on the stock exchange under the ticker symbol AZN. The company is conducting clinical trials to evaluate the drug's safety and efficacy in patients with primary membranous nephropathy and in healthy volunteers.

What phase is ALXN1920 in?

ALXN1920 is in Phase 1 clinical development. A Phase 1 study in healthy participants has been completed, and a Phase 2 study in adult participants with primary membranous nephropathy is currently recruiting. The drug is investigational and has not received approval from the U.S. Food and Drug Administration or other regulatory bodies.

What clinical trials is ALXN1920 in?

ALXN1920 is being studied in two clinical trials. The first, NCT05751642, is a completed Phase 1 study in healthy participants in New Zealand. The second, NCT07157787, is a recruiting Phase 2 study in adults with primary membranous nephropathy, conducted across multiple countries including the United States, Argentina, Australia, Brazil, China, France, Italy, Spain, Taiwan, and the United Kingdom.

Is ALXN1920 the same as other drugs?

ALXN1920 is a distinct investigational drug and is not known to be the same as any other approved or marketed medication. It is a monoclonal antibody being developed by AstraZeneca for primary membranous nephropathy. No alternative names for ALXN1920 have been reported in clinical trial registries.